PEACE: Pediatric Antifungal Comparative Effectiveness

NCT ID: NCT01869829

Last Updated: 2022-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

750 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overarching objective is to develop new evidence-based treatment guidelines for invasive fungal diseases in children. To accomplish that, this protocol will focus on two specific aims: 1) Compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis and for the subset of patients with invasive candidemia; 2) Characterize the incidence rate of inpatient pediatric invasive candidiasis per hospital admissions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multicenter, national and international, prospective observational comparative effectiveness study.

The primary aim of this study is to compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis and for invasive candidemia. The primary effectiveness endpoint for study aim 1 is the comparison of global response at 14 days of antifungal therapy between antifungal therapeutic classes. The secondary effectiveness endpoints for study aim 1 are comparative effectiveness of the 1) global response to antifungal therapy after 30 days and 2) all-cause mortality at 30 days.

The secondary aim is to characterize the frequency of pediatric candidiasis by describing the incidence of pediatric candidiasis relative to all pediatric admissions. For this aim, the investigators will use descriptive statistics to establish the frequency of hospital admissions involving an invasive candidiasis per total hospital admissions and total hospital days during the study period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric Invasive Candidiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pediatric Invasive Candidiasis

Pediatric patients (age \> 120 days and \< 18 years) with documented proven or probable invasive candidiasis

Observational antifungal therapy

Intervention Type DRUG

Observational study of primary antifungal therapy utilized and outcomes, including:

fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin

All agents are given as standard of care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational antifungal therapy

Observational study of primary antifungal therapy utilized and outcomes, including:

fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin

All agents are given as standard of care.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females age \> 120 days and \<18 years
2. Documented proven or probable case of invasive candidiasis
3. Parental/guardian permission (informed consent, if required) and if appropriate, child assent (if required).

Exclusion Criteria

1\) Any history of prior Candida infection within the previous 35 days (These patients will not be eligible for analysis in aim 1 but will be eligible for inclusion of aim 2)
Minimum Eligible Age

120 Days

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital of Philadelphia

OTHER

Sponsor Role collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

Duke University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William J Steinbach, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Theoklis E Zaoutis, MD MSCE

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital of Philadelphia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status

Children's Hospital of Orange County

Orange, California, United States

Site Status

Lucile Packard Children's Hospital at Stanford

Palo Alto, California, United States

Site Status

Rady Children's Hospital

San Diego, California, United States

Site Status

UCSF Benioff Children's Hospital

San Francisco, California, United States

Site Status

Children's Hospital Colorado

Aurora, Colorado, United States

Site Status

Children's National Medical Center

Washington D.C., District of Columbia, United States

Site Status

All Children's Hospital

St. Petersburg, Florida, United States

Site Status

Ann and Robert Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status

Boston Children's Hospital

Boston, Massachusetts, United States

Site Status

Mott Children's Hospital

Ann Arbor, Michigan, United States

Site Status

Children's Hospital and Clinics of Minnesota

Minneapolis, Minnesota, United States

Site Status

Children's Mercy

Kansas City, Missouri, United States

Site Status

Cohen Children's Medical Center of New York

New Hyde Park, New York, United States

Site Status

New York Presbyterian Phyllis and David Komansky Center for Children's Health

New York, New York, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

Cincinnati Children's Medical Center

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic Children's

Cleveland, Ohio, United States

Site Status

OHSU Doernbecher Children's Hospital

Portland, Oregon, United States

Site Status

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

Site Status

Monroe Carell Jr. Children's Hospital at Vanderbilt

Nashville, Tennessee, United States

Site Status

Dell Children's Medical Center

Austin, Texas, United States

Site Status

Texas Children's Hospital

Houston, Texas, United States

Site Status

Seattle Children's

Seattle, Washington, United States

Site Status

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

The Hospital for Sick Children

Toronto, , Canada

Site Status

Centro de Estudios en Infectologia Pediatricia

Cali, , Colombia

Site Status

Centro Medico Imbanaco

Cali, , Colombia

Site Status

3rd Department Pediatrics Aristole University School of Medicine, Hippokration Hospital

Thessaloniki, , Greece

Site Status

Postgraduate Institute of Medical Education and Research

Chandigarh, , India

Site Status

Instuto Giannina Gaslini

Genoa, , Italy

Site Status

King Faisal Specialist Hospital & Research Center

Riyadh, , Saudi Arabia

Site Status

Hospital d'Universitari Vall d'Hebron

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Colombia Greece India Italy Saudi Arabia Spain

References

Explore related publications, articles, or registry entries linked to this study.

Fisher BT, Zaoutis TE, Xiao R, Wattier RL, Castagnola E, Pana ZD, Fullenkamp A, Boge CLK, Ross RK, Yildirim I, Palazzi DL, Danziger-Isakov L, Vora SB, Arrieta A, Yin DE, Aviles-Robles M, Sharma T, Tribble AC, Maron G, Berman D, Green M, Sung L, Romero J, Hauger SB, Roilides E, Belani K, Nolt D, Soler-Palacin P, Lopez-Medina E, Muller WJ, Halasa N, Dulek D, Hussain IZB, Pong A, Hoffman J, Rajan S, Gonzalez BE, Hanisch B, Aftandilian C, Carlesse F, Abzug MJ, Huppler AR, Salvatore CM, Ardura MI, Chakrabarti A, Santolaya ME, Localio AR, Steinbach WJ. Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents. J Pediatric Infect Dis Soc. 2021 Aug 10:piab024. doi: 10.1093/jpids/piab024. Online ahead of print.

Reference Type RESULT
PMID: 34374424 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ipfn.org/

International Pediatric Fungal Network

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01AI103315-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

Pro00045657

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.